Sentences with word «cobimetinib»

The FDA has approved the MEK inhibitor cobimetinib in combination with the BRAF inhibitor vemurafenib for the treatment of advanced metastatic or unresectable BRAF - mutated melanoma.

The most common adverse events seen with cobimetinib / vemurafenib were diarrhea, photosensitivity reaction, nausea, pyrexia, and vomiting.

People taking cobimetinib should avoid sun exposure, wear protective clothing, and a broad spectrum ultraviolet A / ultraviolet B sunscreen to protect against sunburn.

Our work was instrumental in several FDA approvals of breakthrough anti-cancer drugs (vemurafenib, dabrafenib + trametinib, vemurafenib + cobimetinib, pembrolizumab, talimogene laherparepvec) and resulted in almost 100 manuscripts, including New England Journal of Medicine, Lancet, Journal of Clinical Oncology, JAMA, Nature.

The US Food and Drug Administration (FDA) has approved the MEK inhibitor cobimetinib (Cotellic) in combination with the BRAF inhibitor vemurafenib for the treatment of advanced metastatic or unresectable BRAF - mutated melanoma.

With a median follow - up of 14 months, patients assigned to combination treatment with cobimetinib and vemurafenib had a progression - free survival of 12.3 months compared with 7.2 months for those on vemurafenib alone.

Women taking cobimetinib should use effective contraception, as the medication can cause harm to a developing fetus.

We discovered our lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies in our efforts to bring these medicines to patients globally.

Exelixis (EXEL)- Label expansion and new trial data for cabozantinib and cobimetinib should continue to drive upside, while revenue growth and increased gains in market share have also been encouraging.

A validation cohort of 240 patients treated with vemurafenib (BRAF inhibitor) and cobimetinib (MEK inhibitor) yielded similar results.

The targeted therapies are vemurafenib (Zelboraf ®), dabrafenib (Tafinlar ®), trametinib (Mekinist ®), and cobimetinib (Cotellic ®).

According to the FDA, cobimetinib may cause severe side effects including cardiomyopathy or rhabdomyolysis, primary cutaneous malignancies, retinal detachment, hepatotoxicity, hemorrhage, and severe skin rash due to increased sensitivity to sunlight.

All patients were treated with the BRAF inhibitor vemurafenib and were then randomly assigned to cobimetinib or placebo.